Latest News | Biocon Biologics Inks Licence Pact with Janssen for Biosimilar Product

New Delhi, Feb 29 (PTI) Biocon Biologics on Thursday said it has inked a settlement and licence agreement with drug firm Janssen to commercialise its biosimilar product to treat various ailments like psoriasis, Crohn's disease and ulcerative colitis, in the US.

The company's product -- Bmab 1200 -- is a proposed biosimilar to the reference drug Stelara which had sales of USD 7 billion in the US last year.

Also Read | One Vehicle, One FASTag Initiative: Complete FASTag KYC Update by February 29 To Avoid Account Deactivation; Here's a Step-by-Step Guide.

The agreement licenses the company to launch in the US in February 2025, once approved by the US Food and Drug Administration(USFDA), Biocon Biologics said in a statement.

The company is a subsidiary of Biocon Ltd.

Also Read | CUET-UG Exam 2024: Application Process for Common University Entrance Test-UG Begins Today, Exams To Be Conducted in Hybrid Mode; Check Other Details.

Biocon Biologics and Janssen have finalised the settlement agreement to dismiss the pending Inter Partes Review (IPR) before the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademarks Office, the company said.

"We are pleased that this allows the company to be amongst the first launch group to offer a reliable, high quality biosimilar option to patients and healthcare providers in the United States with our bUstekinumab, Bmab 1200," Biocon Biologics CEO & MD Shreehas Tambe stated.

This development enables Biocon Biologics to build further on its existing immunology franchise in the US, he added.

Stelara (Ustekinumab) is a monoclonal antibody medication approved for the treatment of psoriasis, Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)